Jan 14, 2017 02:12 PM IST IST | Source: Moneycontrol.com

Alembic Pharma Q3 PAT may dip 22% to Rs 94 cr: ICICI Securities

Net Sales are expected to decrease by 12.6 percent Q-o-Q (down 17.3 percent Y-o-Y) to Rs 762.3 crore, according to ICICI Securities.

ICICI Securities has come out with its third quarter (October-December) earnings estimates for the Healthcare sector. The brokerage house expects Alembic Pharma to report net profit at 93.7 crore down 21.8% quarter-on-quarter.

Net Sales are expected to decrease by 12.6 percent Q-o-Q (down 17.3 percent Y-o-Y) to Rs 762.3 crore, according to ICICI Securities.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 20.7 percent Q-o-Q (down 63.3 percent Y-o-Y) to Rs 141 crore.

Disclaimer:
The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Sections
Follow us on
Available On